Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 4/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406117 | 0.82 | S1PR2 (0.69) | TSHRHDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL7628886 | 0.81 | HDAC3 (0.49) | TSHRHDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL7214049 | 0.81 | TSHR (0.56) | TSHRCETPS1PR2S1PR4S1PR1 | |
| SCHEMBL10773191 | 0.79 | CETP (0.74) | TSHRHDAC1CETPS1PR2S1PR4 | |
| SCHEMBL8641479 | 0.78 | TSHR (0.58) | TSHRHDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL11510970 | 0.78 | TSHR (0.62) | TSHRHDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL7379078 | 0.78 | TSHR (0.53) | TSHRHDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL5053171 | 0.77 | CYP2D6 (0.48) | TSHRHDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL8736669 | 0.77 | HDAC3 (0.57) | TSHRHDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL8758022 | 0.77 | TSHR (0.67) | TSHRHDAC8HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250152-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | TSHR 3579/4885HDAC8 886/4885HDAC3 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.